ARS Pharmaceuticals, Inc. SPRY
2.98 USD -0.07 (-2.46%)
Nov 3, 2026, 3:24 PM EST
2.92 Day range 3.11
2.91 52-week range 13.15
- YTD
- -74.46%
- 1 year
- -65.49%
Analyst view
Price target (mean) 28.80 +868.1% upside
Now 2.98
- Target (low)
- 25.00
- Target (mean)
- 28.80
- Target (high)
- 32.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 7
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.53 | -0.61 – -0.47 | -0.46 | -15.2% | 31.53M | +100.6% | 3 |
| Next quarter | -0.33 | -0.40 – -0.20 | -0.52 | +36.5% | 51.31M | +57.9% | 3 |
| Current year | -1.76 | -2.05 – -1.45 | -1.74 | -1.1% | 149.35M | +77.2% | 4 |
| Next year | -0.9575 | -1.41 – -0.44 | -1.76 | +45.6% | 273.65M | +83.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 4, 2025 | Roth Capital | Initiated | — | Buy |
| Mar 7, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Jan 14, 2025 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Jan 13, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Oct 8, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 20, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 16, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 20, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 13, 2024 | Raymond James | Upgrade | Outperform | Strong Buy |
| Jul 25, 2024 | Raymond James | Initiated | — | Outperform |
| Mar 11, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 5, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Nov 13, 2023 | Wedbush | Maintained | Outperform | Outperform |
| Sep 21, 2023 | Wedbush | Maintained | Outperform | Outperform |
| Sep 20, 2023 | William Blair | Downgrade | Outperform | Market Perform |
| Aug 14, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 21, 2023 | Wedbush | Maintained | Outperform | Outperform |
| May 18, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| May 12, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| May 10, 2023 | Wedbush | Reiterated | — | Outperform |
| Jan 31, 2023 | Wedbush | Initiated | — | Outperform |
| Jan 4, 2023 | William Blair | Initiated | — | Outperform |
| Dec 13, 2022 | SVB Leerink | Initiated | — | Outperform |